During the recent years, to better understand BC biology, many efforts have been performed, leading to elucidate the heterogeneity of different subtypes [luminal A, luminal B, HER2-positive (HER2+), and triple-negative] susceptible for personalized approach and treatment. The gene discussed is ERBB2; the disease is breast cancer.